Stocks of 10x Genomics Inc. (NASDAQ:TXG) traded higher last session on Wall Street, down -0.66% to $31.68.
According to the data, 10x Genomics Inc. (NASDAQ:TXG) has 11 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $65.00 and a low of $25.00, we find $53.00. Given the previous closing price of $31.89, this indicates a potential upside of 66.2 percent. TXG stock price is now -5.07% away from the 50-day moving average and -26.00% away from the 200-day moving average. The market capitalization of the company currently stands at $3.87B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 1 analysts have issued a hold rating and 7 have given it a buy rating. Brokers who have rated the stock have averaged $49.67 as their price target over the next twelve months.
With the price target of $50, Deutsche Bank recently initiated with Buy rating for 10x Genomics Inc. (NASDAQ: TXG). On August 18, 2022, Goldman Downgraded its previous ‘Neutral’ rating to ‘Sell’ on the stock reducing its target price from $55 to quote $35, while ‘Canaccord Genuity’ rates the stock as ‘Buy’.
In other news, Saxonov Serge, Chief Executive Officer sold 2,676 shares of the company’s stock on Nov 22. The stock was sold for $91,158 at an average price of $34.07. Upon completion of the transaction, the Chief Executive Officer now directly owns 974,926 shares in the company, valued at $30.89 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 22, Chief Financial Officer McAnear Justin J. sold 1,626 shares of the business’s stock. A total of $55,392 was realized by selling the stock at an average price of $34.07. This leaves the insider owning 76,764 shares of the company worth $2.43 million. Insiders disposed of 133,774 shares of company stock worth roughly $4.24 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TXG stock. A new stake in 10x Genomics Inc. shares was purchased by SVB WEALTH LLC during the first quarter worth $31,856,000. ARDEVORA ASSET MANAGEMENT LLP invested $17,231,000 in shares of TXG during the first quarter. In the first quarter, CIBC ASSET MANAGEMENT INC acquired a new stake in 10x Genomics Inc. valued at approximately $10,626,000. DUQUESNE FAMILY OFFICE LLC acquired a new stake in TXG for approximately $3,698,000. RHENMAN & PARTNERS ASSET MANAGEMENT AB purchased a new stake in TXG valued at around $2,376,000 in the second quarter. In total, there are 392 active investors with 90.30% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $31.59 for 10x Genomics Inc. (NASDAQ: TXG). During the past 12 months, 10x Genomics Inc. has had a low of $23.81 and a high of $154.10. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.00, and a quick ratio of 4.30. The fifty day moving average price for TXG is $33.37 and a two-hundred day moving average price translates $42.81 for the stock.
The latest earnings results from 10x Genomics Inc. (NASDAQ: TXG) was released for Jun, 2022. According to the Health Information Services Company, earnings per share came in at -$0.57, missing analysts’ expectations of -$0.39 by -0.18. This compares to -$0.15 EPS in the same period last year. The net profit margin was -33.20% and return on equity was -21.00% for TXG. The company reported revenue of $131.07 million for the quarter, compared to $125.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.61 percent. For the current quarter, analysts expect TXG to generate $129.58M in revenue.
10x Genomics Inc.(TXG) Company Profile
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
